Home » Stocks » NERV

Minerva Neurosciences, Inc. (NERV)

Stock Price: $3.71 USD -0.22 (-5.60%)
Updated November 24, 4:00 PM EST - Market closed
After-hours: $3.77 +0.06 (1.62%) Nov 24, 7:55 PM

Stock Price Chart

Key Info

Market Cap 158.32M
Revenue (ttm) 41.18M
Net Income (ttm) -20.65M
Shares Out 42.67M
EPS (ttm) -0.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $3.71
Previous Close $3.93
Change ($) -0.22
Change (%) -5.60%
Day's Open 3.97
Day's Range 3.65 - 4.00
Day's Volume 698,120
52-Week Range 1.81 - 15.22

More Stats

Market Cap 158.32M
Enterprise Value 125.86M
Earnings Date (est) Mar 15, 2021
Ex-Dividend Date n/a
Shares Outstanding 42.67M
Float 34.92M
EPS (basic) -0.52
EPS (diluted) -0.52
FCF / Share -0.97
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.92M
Short Ratio 7.70
Short % of Float 8.36%
Beta 1.49
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.85
PB Ratio 2.71
Revenue 41.18M
Operating Income -23.22M
Net Income -20.65M
Free Cash Flow -40.84M
Net Cash 32.46M
Net Cash / Share 0.76
Gross Margin 100.00%
Operating Margin -56.40%
Profit Margin -50.20%
FCF Margin -99.19%
ROA -3.00%
ROE -36.38%
ROIC -120.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 4
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(85.98% upside)
Current: $3.71
Target: 6.90
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-75.87-51.73-41.17-30.19-26.11-54.87-3.17
Net Income-72.18-50.17-31.52-31.05-27.08-56.90-3.26
Shares Outstanding39.0138.7937.9431.5123.4112.724.19
Earnings Per Share-1.85-1.29-0.83-0.99-1.16-4.47-0.78
Operating Cash Flow-43.43-41.943.09-25.69-24.27-35.96-2.16
Capital Expenditures---0.05---0.05-
Free Cash Flow-43.43-41.943.04-25.69-24.27-36.01-2.16
Cash & Equivalents45.9588.1012883.0632.2818.581.82
Total Debt0.28-3.968.699.94-0.06
Net Cash / Debt45.6788.1012474.3722.3518.581.76
Book Value27.7890.2613210655.3251.5020.18
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Minerva Neurosciences, Inc.
Country United States
Employees 13
CEO Rémy Henri Luthringer

Stock Information

Ticker Symbol NERV
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NERV
IPO Date July 1, 2014


Minerva Neurosciences, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia. The company is also developing seltorexant that has completed Phase IIb clinical trial for treating insomnia and major depressive disorders; and MIN-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the roluperidone worldwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.